In the last trading session, 2.77 million ABVC BioPharma Inc (NASDAQ:ABVC) shares changed hands as the company’s beta touched 0.56. With the company’s per share price at $1.55 changed hands at -$0.04 or -2.52% during last session, the market valuation stood at $6.12M. ABVC’s last price was a discount, traded about -1106.45% off its 52-week high of $18.70. The share price had its 52-week low at $0.67, which suggests the last value was 56.77% up since then. When we look at ABVC BioPharma Inc’s average trading volume, we note the 10-day average is 2.62 million shares, with the 3-month average coming to 2.08 million.
Analysts gave the ABVC BioPharma Inc (ABVC) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended ABVC as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. ABVC BioPharma Inc’s EPS for the current quarter is expected to be $0.
ABVC BioPharma Inc (NASDAQ:ABVC) trade information
Instantly ABVC was in red as seen at the end of in last trading. With action 46.23%, the performance over the past five days has been green. The drop to weekly highs of 1.7800 on Friday, 11/17/23 subtracted -2.52% to the stock’s daily price. The company’s shares are showing year-to-date downside of -75.20%, with the 5-day performance at 46.23% in the green. However, in the 30-day time frame, ABVC BioPharma Inc (NASDAQ:ABVC) is 68.48% up. Looking at the short shares, we see there were 0.98 million shares sold at short interest cover period of 0.21 days.
The consensus price target for the stock as assigned by Wall Street analysts is $20.20, meaning bulls need an upside of 92.33% from its current market value. According to analyst projections, ABVC’s forecast low is $20.20 with $20.20 as the target high. To hit the forecast high, the stock’s price needs a -1203.23% plunge from its current level, while the stock would need to soar -1203.23% for it to hit the projected low.
ABVC BioPharma Inc (ABVC) estimates and forecasts
Year-over-year growth is forecast to reach -27.80% down from the last financial year.
1 analysts are of the opinion that ABVC BioPharma Inc’s revenue for the quarter ending Sep 2023 will be $16k. The company’s revenue for the corresponding quarters a year ago was $313k and $42k respectively. The estimates for the next quarter sales put growth at -61.90%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -7.69%.
ABVC BioPharma Inc is expected to release its next quarterly earnings report on November 15.
ABVC BioPharma Inc (NASDAQ:ABVC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 38.99% of ABVC BioPharma Inc shares while 2.00% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 3.28%. There are 2.00% institutions holding the ABVC BioPharma Inc stock share, with Vanguard Group Inc the top institutional holder. As of Jun 29, 2023, the company held 0.98% of the shares, roughly 38751.0 ABVC shares worth $20131.0.
Geode Capital Management, LLC holds the second largest percentage of outstanding shares, with 0.35% or 13928.0 shares worth $7235.0 as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Fidelity Extended Market Index Fund. With 37514.0 shares estimated at $19488.0 under it, the former controlled 0.95% of total outstanding shares. On the other hand, Fidelity Extended Market Index Fund held about 0.22% of the shares, roughly 8778.0 shares worth around $5969.0.